NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Aclaris Therapeutics, Inc. (ACRS) Stock Analysis

Aclaris Therapeutics, Inc. (ACRS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACRS

$6.17

+$0.22 (+3.70%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACRS with… →

ACRS Key Statistics

As of Sep 4, 2026
Trading
Open
$5.97
Previous Close
$5.95
Day's Range
5.87–6.20
52-Week Range
1.74–6.60
Volume
1.75M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.80
Valuation
Market Cap
$908.22M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
110.50
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.58
Financials (FY)
Revenue (FY)
$7.83M−58.19%
Net Income (FY)
−$64.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
147.20M
1-Year Return
+198.07%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.90M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACRS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+104.98%
2025+21.37%
2024+136.19%
2023−93.33%
2022+8.32%
2021+124.73%
2020+242.33%
2019−74.42%
2018−70.03%
2017−9.14%
2016 (partial year)+44.67%

As of September 4, 2026.

ACRS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$7.83M−$64.92M−829.6%
2024$18.72M−$132.07M−705.5%
2023$31.25M−$88.48M−283.1%
2022$29.75M−$86.91M−292.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.83M$542.00K−$74.08M−$64.92M−829.6%
2024$18.72M$3.26M−$52.53M−$132.07M−705.5%
2023$31.25M$13.17M−$116.31M−$88.48M−283.1%
2022$29.75M$17.79M−$85.15M−$86.91M−292.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACRS Valuation vs Biotechnology Median

Median of 656 stocks
MetricACRSBiotechnology medianvs median
P/S ratio110.5015.267.2x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Aclaris Therapeutics, Inc. (ACRS) at $908.22M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 69.

Over the past 52 weeks the price has ranged from $1.74 to $6.60. The most recent close on file for ACRS is $6.17, dated September 4, 2026. That is +$0.22 (+3.70%) against the previous close. The latest close sits 254.6% above that 52-week low.

Financial Health

In fiscal 2025, Aclaris Therapeutics, Inc. reported revenue of $7.83M. Against the prior fiscal year total of $18.72M, that is a change of −58.19%. The same year closed with a net loss of $64.92M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.58.

Across the 4 fiscal years on file, revenue moves from $29.75M in 2022 to $7.83M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 110.5 times revenue. On price-to-sales that is 7.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.8. Daily returns over the trailing 10 years annualize to a volatility of 110.49%. The trailing one-year price return is +198.07%. Across 10 years the annualized return works out at −11.47%.

Growth & Income

The record shows no dividend for ACRS.

The strongest complete calendar year on file is 2020 at +242.33%; the weakest is 2023 at −93.33%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +104.98% year to date.

Peer Comparison

Aclaris Therapeutics, Inc. (ACRS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aclaris Therapeutics, Inc. ACRS $908.22M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Aclaris Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Visit website →